Skip to main content
Evidence Snapshot

KARPAS-299

CHEMBL2366156 CELL-LINE Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:06:30Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2366156
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats KARPAS-299 as ChEMBL target CHEMBL2366156. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
KARPAS-299
CELL-LINE · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL2366156
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why KARPAS-299 matters

As of 2026-09-13

KARPAS-299 is reviewed as KARPAS-299; the current evidence base includes 28 approved drugs, 783 compounds, and 148 assays, with lead potency reaching pChEMBL 9.9.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 28 approved drugs, 783 compounds, and 148 assays for this target. The dominant activity type is IC50. CHEMBL5614312 is the current potency anchor at pChEMBL 9.9.

Use CHEMBL5614312 as the tractability anchor when discussing potency (pChEMBL 9.9).

Activity source · ChEMBL 36 via Core Engine
28 approved pChEMBL 9.9
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why KARPAS-299 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

783
Total Compounds
148
Total Assays
28
Approved Drugs
IC50: 806.0, EC50: 2.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL5614312
 9.9 IC50 —
No preferred name
CHEMBL11417
 9.4 IC50 Clinical
No preferred name
CHEMBL5205301
 9.2 IC50 —
No preferred name
CHEMBL4764610
 8.7 IC50 —
No preferred name
CHEMBL509032
 8.7 IC50 —

Approved Drugs

Structure Compound First Approval
REPOTRECTINIB
CHEMBL4298138
 2023
ENTRECTINIB
CHEMBL1983268
 2019
LORLATINIB
CHEMBL3286830
 2018
ALECTINIB
CHEMBL1738797
 2015
CERITINIB
CHEMBL2403108
 2014
CRIZOTINIB
CHEMBL601719
 2011
TEMSIROLIMUS
CHEMBL1201182
 2007
SIROLIMUS
CHEMBL413
 1999
GEMCITABINE
CHEMBL888
 1996
DOCETAXEL
CHEMBL3545252
 1995
VINORELBINE
CHEMBL553025
 1994
PACLITAXEL
CHEMBL428647
 1992
DOXORUBICIN
CHEMBL53463
 1974
METHOTREXATE
CHEMBL34259
 1953
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:06:30Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2366156